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| INTRODUCTION
Multiple sclerosis (MS) is severe chronic, inflammatory, demyelinating disease of the central nervous system (CNS). There is common belief that complex interplay between various genetic and environmental factors contributes to MS. Vitamin D, aside from regulation of the level of calcium and phosphorus within the human body, influences the immune system significantly. Previous studies have found that vitamin D deficiency in adolescence (as one of the environmental factors) can play a significant role in increasing the risk of developing autoimmune diseases including MS (Fitzgerald et al., 2015; Solomon, 2011) . This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. − normal level: 30-50 ng/mL (75-125 nmol/L), − suboptimal level: 20-30 ng/mL (50-75 nmol/L), − deficiency level: < 20 ng/mL (< 50 nmol/L) (Płudowski et al., 2013) .
The aforementioned accurate definition of 25(OH)D levels in patients may be critical while evaluating the efficiency of vitamin D supplementation in remitting-relapsing MS (RRMS) in clinical trials.
Aforementioned definitions are predominantly based on bone calcium metabolism outcomes, since optimal 25(OH)D levels for immune regulation in MS may be higher (Fitzgerald et al., 2015; Munger, Levin, Hollis, Howard, & Ascherio, 2006 (Alharbi, 2015; Ascherio et al., 2014; Munger et al., 2004 Munger et al., , 2006 Simpson et al., 2010) and the correlation between vitamin D status and clinical course of the disease (Rosiak & Zagożdżon, 2012; Runia, Hop, de Rijke, Buljevac, & Hintzen, 2012) .
The aim of this study was to investigate the relationship between the vitamin D status in serum and clinical and radiological outcomes in a treated population in Poland.
| MATERIALS AND METHODS
| Ethics statement
The study was conducted in accordance with the Helsinki Declaration and the rules of Good Clinical Practice. Regional Ethical Committee in Bydgoszcz approved the study protocol, and all patients gave written informed consent before trial entry. The secondary analyses presented in this manuscript were conducted anonymously.
| Study population
The study population was determined according to the following criteria. Inclusion criteria result from administrative limitations: all patients who want to take part in the treatment founded by the Polish National Health Fund have to meet inclusion criteria described in regulations (Polish National Health Fund, 2016) . Recruitment method was convenience sample. Such recruitment procedure aimed at a sample with sufficient clinical activity to be able to measure associations. 
| Intervention and assessment
The study design was a prospective before-after study (BAS).
Samples were collected at the start of the study and at the end of the study. Patients were recruited at the beginning of the 12-month period of the treatment, and assessed after the 12 months of the therapy. The immunomodulatory treatment comprised of therapy using interferon beta 1a (INFβ-1a) (subcutaneous or intramuscular), interferon beta 1b (INF β-1b), and glatiramer acetate (GA). Patients were assessed neurologically after 12 months of treatment. The level of disability was also assessed using Extended Disability Status Scale (EDSS). Increase ofEDSS > 1 point sustained over 30 days was assessed as the progression of the disease.
Blood samples were collected during fasting in the morning.
| Statistical analysis
Where available, descriptive characteristics of study subjects were reported as percentages for categorical variables and mean ± SD for continuous variables. Otherwise, median, quartiles, and minimal and maximal values were used. Respectively, parametric and nonparametric tests were used. Fisher's Exact test was used in the analysis of contingency tables. Statistical dependencies between variables were calculated using Spearman's rank correlation coefficient (Spearman's rho). A p-value < 0.05 was considered to be significant. Statistical analysis was performed using the Statistica 10 software.
| RESULTS
The average 25(OH)D level in the study group was 18,6 ng/ml. The largest group (53 patients, i.e., 63.8%) showed significant vitamin D deficiency (<20 ng/ml). Eighteen patients (21.7%) showed the sub- 5.5% vs. 8.3%, p < .05).
Only changes reflected in T2-weighted scanning sequences were statistically significant (r = −.28, p < .05). Statistically significant differences between groups were not observed in EDSS outcomes. Results of the study are presented below (Table 2, Figure 1 ). We consolidated numbers of events in the suboptimal and normal levels due to statistical reasons (Table 2) .
| DISCUSSION
The aim of the study was to investigate the relationship between the level of 25(OH)D in serum and clinical and radiological outcomes in a population treated using the immunomodulatory treatment in multiple sclerosis-there are a few studies concerning this important issue.
The prevalence of MS varies by location on the globe. It increases with latitude (i.e., when traveling from the equator toward northern or southern pole). Despite growing number of publications, the mechanisms influencing the initiation, perpetuation, and therapy of MS remain enigmatic, although it is established that a combination of genetic predisposition and environmental stimulation is required (Nedeljkovic et al., 2016; Selmi, Papini, Pugliese, Alcaro, & Gershwin, 2011) . Thus, true may be an assumption that vitamin D deficiency can constitute important element among causative agents of the MS, and it may explain such altered MS incidence (Ascherio et al., 2014) .
Paul Goldberg is the first author who mentioned the hypothesis linking a deficiency of vitamin D and MS prevalence (1974) . He studied the relationship between environmental determinants (such as sunlight, dietary factors, etc.) and MS prevalence (Goldberg, 1974) . 
Low level of 25(OH)D is more often observed in patients with
MS than in general population (Ascherio, Mungen, & Simon, 2010; McDowell et al., 2011; Munger et al., 2004) . The normal level of 25(OH)D was observed in 14.5% of patients with MS. A significant deficiency of 25(OH)D was observed in 63.8% of patients with MSthey require pharmacological supplementation (Ascherio et al., 2014) . On the other hand, a recent study Røsjø et al., 2015 showed results of MRI and inflammation markers across patients categorized by mean vitamin D values, suggesting a lack of vitamin D influence on interferon-β1a treatment effects.
The main limitation of this study is a relatively small sample and lack of control group. Number of patients (n = 83) is similar to the lower values from the previous studies-it varied from n = 88 (study by Røsjø et al., 2015) to n = 465 (study by Munger et al., 2014) and may be regarded as proper for preliminary findings. Aforementioned number of patients seems to be appropriate for main aim of the study: Differences in the biological effects of vitamin D metabolites were previously described (Correale, Ysrraelit, & Gaitan, 2010) . These outcomes need further research. We also consolidated number of events in the suboptimal and normal levels in Table 2 due to small numbers.
Another limitation was the various vitamin D assays used.
There may be assumption that the distribution of immune-modulating treatments (IFNb+GA) between all treatment groups influences results. But article by McGraw and Lublin showed lack of statistically relevant differences between IFNb, GA, and INFb+GA (McGraw & Lublin, 2013) .
Assumption that disease activity generally improved with higher 25(OH)D levels may also be true, but effect modification by treatment class is still discussed and needs additional research, for example, no significant associations were found for relapses (Rotstein et al., 2015) .
Thus, aforementioned analysis may diminish results of the study.
Study by Rotstein et al., 2015 is relatively new and is still discussed (Konieczka, Koch, Binggeli, Schoetzau, & Kesselring, 2016; Polivka, Polivka, Krakorova, Peterka, & Topolcan, 2016) .
We took into consideration diverse disease-modifying treatments (DMTs) but we excluded many of them such as treatment for secondary disease or simultaneous rehabilitation. Patients in different vitD strata were assessed as comparable regarding baseline MRI and DMTs.
Evidence above supports the hypothesis that 25(OH)D levels (e.g., through supplementation) may influence the course of the therapy in MS patients treated with IFN-beta-1b; but there is still a lack of common agreement. We have high hopes for a settlement to this dispute during our further studies. To avoid aforementioned limitations, directions of our further studies will cover monitoring and managing 25(OH)D levels in early MS patients treated with IFN-beta-1b, and also investigating the biological mechanisms underlying aforementioned observations.
To sum up, vitamin D insufficiency is regarded as a potential risk factor for MS, associated with a higher disease activity. Based on the current knowledge, we cannot anticipate whether vitamin D bioavailability is associated with RRMS patients. Results of previous studies addressing effects of oral high-dose vitamin D are not consistent;
there is a need for larger studies such as SOLAR. But we believe that our outcomes add an important element to explaining the vitamin D role in MS patients.
| CONCLUSIONS
Our findings confirm that deficiency of vitamin D in patients with MS is correlated with clinical and radiological course of the disease.
Further research, including studies comparing the effectiveness of the immunomodulatory treatment in MS after vitamin D supplementation, can constitute an important tool to optimizing the treatment in patients with MS.
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